We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

This study is currently recruiting participants.
Verified September 2017 by Allergan
Sponsor:
ClinicalTrials.gov Identifier:
NCT02828020
First Posted: July 11, 2016
Last Update Posted: September 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Allergan
  Purpose
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.

Condition Intervention Phase
Migraine, With or Without Aura Drug: Ubrogepant Drug: Placebo-matching Ubrogepant Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Resource links provided by NLM:


Further study details as provided by Allergan:

Primary Outcome Measures:
  • Percentage of Participants with Pain Freedom at 2 Hours after Initial Dose [ Time Frame: 2 Hours ]
  • Percentage of Participants with Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours after Initial Dose [ Time Frame: 2 Hours ]

Secondary Outcome Measures:
  • Percentage of Participants with Sustained Pain Freedom from 2 to 24 Hours after Initial Dose [ Time Frame: 2 to 24 Hours ]
  • Percentage of Participants with Pain Relief at 2 Hours after the Initial Dose [ Time Frame: 2 Hours ]
  • Percentage of Participants with Sustained Pain Relief from 2 to 24 Hours after the Initial Dose [ Time Frame: 2 to 24 Hours ]
  • Percentage of Participants with the Absence of Photophobia at 2 Hours after the Initial Dose [ Time Frame: 2 Hours ]
  • Percentage of Participants with the Absence of Phonophobia at 2 Hours after the Initial Dose [ Time Frame: 2 Hours ]
  • Percentage of Participants with Absence of Nausea at 2 Hours after the Initial Dose [ Time Frame: 2 Hours ]
  • Percentage of Participants Satisfied or Extremely Satisfied at 2 Hours after Initial Treatment using the 7-Point Satisfaction with Study Medication Scale [ Time Frame: 2 Hours ]
  • Percentage of Participants with Sustained Pain Freedom from 2 to 48 Hours after Initial Dose [ Time Frame: 2 to 48 Hours ]
  • Percentage of Participants with Sustained Pain Relief from 2 to 48 Hours after the Initial Dose [ Time Frame: 2 to 48 Hours ]
  • Percentage of Participants able to Function Normally at 2 Hours after Initial Treatment using the 4-Point Functional Disability Scale [ Time Frame: 2 Hours ]

Estimated Enrollment: 1650
Actual Study Start Date: July 22, 2016
Estimated Study Completion Date: November 13, 2017
Estimated Primary Completion Date: November 13, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ubrogepant 50 mg
1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant tablet orally for treatment of a qualifying migraine attack. Participants may receive a second dose 2 hours after initial treatment if applicable.
Drug: Ubrogepant
50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Drug: Placebo-matching Ubrogepant
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Experimental: Ubrogepant 100 mg
2 ubrogepant 50 mg tablets orally for treatment of a qualifying migraine attack. Participants may receive a second dose 2 hours after initial treatment if applicable.
Drug: Ubrogepant
50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo Comparator: Placebo
2 placebo-matching ubrogepant tablets orally for treatment of a qualifying migraine attack. Participants may receive a second dose 2 hours after initial treatment if applicable.
Drug: Placebo-matching Ubrogepant
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, beta version
  • Migraine onset before age 50
  • History of migraines typically lasting between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
  • History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the previous 3 months.

Exclusion Criteria:

  • Difficulty distinguishing migraine headache from other headaches
  • Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per month in the previous 3 months
  • Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • Required hospital treatment of a migraine attack 3 or more times in the previous 6 months
  • Has a chronic non-headache pain condition requiring daily pain medication
  • Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • Has a history of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of investigational product; patients with prior gastric bariatric interventions which have been reversed are not excluded
  • Has a history of hepatitis within previous 6 months.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02828020


Contacts
Contact: Clinical Trials Registry Team 1-800-347-4500 IR-CTRegistration@allergan.com

  Show 93 Study Locations
Sponsors and Collaborators
Allergan
Investigators
Study Director: Adele Thorpe Allergan
  More Information

Additional Information:
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT02828020     History of Changes
Other Study ID Numbers: UBR-MD-01
First Submitted: July 7, 2016
First Posted: July 11, 2016
Last Update Posted: September 11, 2017
Last Verified: September 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases